Bafilomycin A1

Drug Profile

Bafilomycin A1

Latest Information Update: 21 Jan 2008

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antidementias; Antiulcers; Antivirals; Calcium regulators; Macrolides; Neuroprotectants; Osteoporosis therapies
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Gastrointestinal disorders; Influenza virus infections; Postmenopausal osteoporosis

Most Recent Events

  • 25 Jan 2000 A preclinical study has been added to the pharmacodynamics section
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
  • 04 Sep 1998 No-Development-Reported for Gastrointestinal disorders in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top